Study Information

Alliance Study ID: CALGB-60102

NCT Study ID (ClinicalTrials.gov): NCT00048971

Alliance Committee: Experimental Therapeutics

Disease or Cancer Type: Colorectal / Colon / Rectal Cancer

Alliance Study Chair: Mark J. Ratain, MD

Status: COMPLETED


Study Description

RATIONALE: Genetic testing may help predict how patients will respond to chemotherapy drugs and may help doctors plan more effective treatment with fewer side effects.

PURPOSE: Genetic study to determine how genes affect the severity of diarrhea in patients with stage III colon cancer who are receiving chemotherapy.

Related Publications

For publications related to this and other clinical trials, visit the Alliance Publications Application.

Data Sources & Contacts

Related Alliance Trials